JP2015505295A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505295A5 JP2015505295A5 JP2014512088A JP2014512088A JP2015505295A5 JP 2015505295 A5 JP2015505295 A5 JP 2015505295A5 JP 2014512088 A JP2014512088 A JP 2014512088A JP 2014512088 A JP2014512088 A JP 2014512088A JP 2015505295 A5 JP2015505295 A5 JP 2015505295A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- article
- container
- dosage form
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161489017P | 2011-05-23 | 2011-05-23 | |
| US61/489,017 | 2011-05-23 | ||
| PCT/US2012/039219 WO2012162439A2 (en) | 2011-05-23 | 2012-05-23 | Compositions comprising fusidic acid and packages therefor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015505295A JP2015505295A (ja) | 2015-02-19 |
| JP2015505295A5 true JP2015505295A5 (cg-RX-API-DMAC7.html) | 2015-07-16 |
| JP6072778B2 JP6072778B2 (ja) | 2017-02-01 |
Family
ID=47218064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014512088A Active JP6072778B2 (ja) | 2011-05-23 | 2012-05-23 | フシジン酸を含む組成物およびそのためのパッケージ |
Country Status (3)
| Country | Link |
|---|---|
| US (4) | US20140088062A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6072778B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012162439A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004080391A2 (en) | 2003-03-10 | 2004-09-23 | Optimer Pharmaceuticals, Inc. | Novel antibacterial agents |
| JP5698979B2 (ja) | 2007-10-25 | 2015-04-08 | センプラ ファーマシューティカルズ，インコーポレイテッド | マクロライド系抗菌剤の調製プロセス |
| HRP20160222T1 (hr) | 2008-10-24 | 2016-04-08 | Cempra Pharmaceuticals, Inc. | Biozaštite uporabom makrolida koji sadrže triazol |
| US9937194B1 (en) | 2009-06-12 | 2018-04-10 | Cempra Pharmaceuticals, Inc. | Compounds and methods for treating inflammatory diseases |
| WO2011032052A1 (en) | 2009-09-10 | 2011-03-17 | Cempra Pharmaceuticals, Inc. | Methods for treating malaria, tuberculosis and mac diseases |
| EP2571506B1 (en) | 2010-05-20 | 2017-05-10 | Cempra Pharmaceuticals, Inc. | Processes for preparing macrolides and ketolides and intermediates therefor |
| KR20130120458A (ko) | 2010-09-10 | 2013-11-04 | 셈프라 파마슈티컬스, 인크. | 질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드 |
| WO2013148891A1 (en) | 2012-03-27 | 2013-10-03 | Cempra Pharmaceuticals, Inc. | Parenteral formulations for administering macrolide antibiotics |
| EP2968801B1 (en) | 2013-03-14 | 2018-09-26 | Cempra Pharmaceuticals, Inc. | Methods for treating respiratory diseases and formulations therefor |
| CN105188712A (zh) | 2013-03-15 | 2015-12-23 | 森普拉制药公司 | 用于制备大环内酯抗菌剂的收敛方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0300073A1 (en) * | 1987-07-22 | 1989-01-25 | Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) | Use of fusidic acid in the treatment of aids-related complex and full-blown aids |
| US6103884A (en) * | 1996-03-27 | 2000-08-15 | The University Of Michigan | Glycosylated analogs of fusidic acid |
| JPH11189547A (ja) * | 1997-12-26 | 1999-07-13 | Taisho Pharmaceut Co Ltd | 安定化されたニコランジル製剤及びその製造方法 |
| JP2005103148A (ja) * | 2003-10-01 | 2005-04-21 | Nisshin Kyorin Pharmaceutical Co Ltd | ５−アミノサリチル酸の保存方法及び保存システム |
| JPWO2005099698A1 (ja) * | 2004-04-15 | 2008-03-06 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 安定化された４−アミノ−５−クロロ−Ｎ−［（１Ｒ，３ｒ，５Ｓ）−８−メチル−８−アザビシクロ［３．２．１］オクタ−３−イル］−２−［１−メチルブタ−２−インイルオキシ］ベンズアミド含有組成物 |
| CA2574188A1 (en) * | 2004-07-16 | 2006-01-26 | Cipla Limited | Anti-histaminic composition |
| US20060076536A1 (en) * | 2004-09-29 | 2006-04-13 | Barshied Scott R | Oxygen scavenging pharmaceutical package and methods for making same |
| EP1977734A1 (en) * | 2007-04-03 | 2008-10-08 | Royal College of Surgeons in Ireland | A method of producing fast dissolving tablets |
| CN100566704C (zh) * | 2007-10-12 | 2009-12-09 | 西藏康欣药业有限公司 | 夫西地酸钠冻干粉针剂 |
| CN102065893A (zh) * | 2008-04-15 | 2011-05-18 | 萨可德公司 | Lfa-1拮抗剂向胃肠系统的递送 |
| HRP20130515T1 (en) * | 2009-02-18 | 2013-07-31 | Sulur Subramaniam Vanangamudi | A process to make fusidic acid cream |
| US20120035144A1 (en) * | 2009-04-20 | 2012-02-09 | Apex Laboratories Private Limited | Medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a corticosteroid, and an antifungal agent, and a process to make it. |
| US8450300B2 (en) * | 2009-07-13 | 2013-05-28 | Cempra Pharmaceuticals Inc. | Fusidic acid dosing regimens for treatment of bacterial infections |
-
2012
- 2012-05-23 JP JP2014512088A patent/JP6072778B2/ja active Active
- 2012-05-23 WO PCT/US2012/039219 patent/WO2012162439A2/en not_active Ceased
- 2012-05-23 US US14/119,542 patent/US20140088062A1/en not_active Abandoned
-
2018
- 2018-03-16 US US15/923,135 patent/US20190060457A1/en not_active Abandoned
-
2019
- 2019-04-02 US US16/372,687 patent/US20200030448A1/en not_active Abandoned
-
2021
- 2021-09-03 US US17/466,366 patent/US20220233699A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015505295A5 (cg-RX-API-DMAC7.html) | ||
| JP2010132695A5 (cg-RX-API-DMAC7.html) | ||
| BR112013032122A2 (pt) | liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos | |
| JP2012515720A5 (cg-RX-API-DMAC7.html) | ||
| JP2015078230A5 (cg-RX-API-DMAC7.html) | ||
| EA201690102A1 (ru) | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе | |
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| JP2010222367A5 (cg-RX-API-DMAC7.html) | ||
| JP2016510019A5 (cg-RX-API-DMAC7.html) | ||
| JP2012517449A5 (cg-RX-API-DMAC7.html) | ||
| MX345404B (es) | Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol- 2-il]-1h-quinolin-2-ona. | |
| JP2012236834A5 (cg-RX-API-DMAC7.html) | ||
| JP2010520246A5 (cg-RX-API-DMAC7.html) | ||
| JP2014530801A5 (cg-RX-API-DMAC7.html) | ||
| CA2692191C (en) | Use of conjugates of hyaluronic acid in the local treatment of hyperproliferative skin diseases | |
| ECSP13012399A (es) | Un nuevo conjugado de granulocito colonia-estimulante factor (g-csf) con polietileno | |
| JP2012508256A5 (cg-RX-API-DMAC7.html) | ||
| HK1203050A1 (en) | Novel dosage and formulation | |
| MX2014002480A (es) | Uso del compuesto organico para el tratamiento del sindrome de noonan. | |
| WO2011093815A3 (en) | Pharmaceutical compositions comprising formoterol and mometasone | |
| WO2011093818A3 (en) | Pharmaceutical compositions comprising salmeterol and fluticasone | |
| JP2016537364A5 (cg-RX-API-DMAC7.html) | ||
| JP2016538288A5 (cg-RX-API-DMAC7.html) | ||
| JP2015521647A5 (cg-RX-API-DMAC7.html) | ||
| JP2013519695A5 (cg-RX-API-DMAC7.html) |